Loading
GeneDx Holdings Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Casdin Capital, LLC, was filed 08 Jun 2026.
Insider Decl.
710
Thresholds
n/a
Buy Volume
€167M
48 ops. · all time
Sell Volume
€217M
387 ops. · all time
Who traded when
BuySaleKatherine Stueland71 sales
Kevin Feeley71 sales
Keith A. Meister21 buys
Joshua Ruch15 sales
Bryan Dechairo12 sales
Jason Ryan7 sales
+1 other insider
Since the insiders bought
- +16.7%Entry US$56.33 · Close 16 Oct 2026 US$65.72
- +53.9%Entry US$42.69 · Close 16 Oct 2026 US$65.72
- +4855.7%Entry US$1.40 · Close at T+365 US$69.38
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate GeneDx Holdings Corp. Strong Buy (bullish), based on 8 analysts. Average price target: US$93.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,381 of 26,280 companies
32.6
score / 100
Value35
Quality30
FCF yld0.7%
Earn yld-1.0%
EV/EBITDA·
ROE-41%
Gross mgn70%
Net mgn-4.9%
Debt/EBITDA9.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$68.94
Analyst consensus
8 analystsStrong buy
US$83.00Target US$93.50(+36%)US$103.00
Income statement
RevenueUS$427.5M
Gross profitUS$298.2M70% margin
EBITDAUS$12.1M3% margin
Net income-US$21M-23.4% margin
Valuation
PER (forward)57.5x
P/Book8.4x
Beta1.97
Balance sheet & cash
Market capUS$2.1B
Total debtUS$113.2M
Free Cash FlowUS$14.3M
Debt / Equity69%
Profitability & ownership
ROE-40.8%
ROA-7.9%
% insiders7.7%
% institutions108.7%
Last declaration on 18 September 2026
Declarations710 total
1,470 shares@ US$98.270.0074% mcap8.4% of flowClass A Common StockSEC:0001944119-26-000037:4
1,525 shares@ US$96.90090.0076% mcap2.1% of flowClass A Common StockSEC:0001689575-26-000032:3
18,750 shares0Class A Common StockSEC:0001689575-26-000032:0
7,197 shares0Class A Common StockSEC:0001944119-26-000037:0
1,146 shares0Class A Common StockSEC:0002083937-26-000005:0
1,079 shares@ US$98.9950.0055% mcap6.2% of flowClass A Common StockSEC:0001944119-26-000037:5
4,141 shares@ US$98.270.021% mcap5.7% of flowClass A Common StockSEC:0001689575-26-000032:4
586 shares@ US$94.2580.0028% mcap3.2% of flowClass A Common StockSEC:0001944119-26-000037:1
52 shares@ US$95.4050.0003% mcap0.3% of flowClass A Common StockSEC:0001944119-26-000037:2
541 shares@ US$96.90090.0027% mcap3.1% of flowClass A Common StockSEC:0001944119-26-000037:3
1,648 shares@ US$94.2580.0080% mcap2.2% of flowClass A Common StockSEC:0001689575-26-000032:1
148 shares@ US$95.4050.0007% mcap0.2% of flowClass A Common StockSEC:0001689575-26-000032:2
3,039 shares@ US$98.9950.015% mcap4.2% of flowClass A Common StockSEC:0001689575-26-000032:5
2,462 shares0Class A Common StockSEC:0001944119-26-000035:0
6,547 shares0Class A Common StockSEC:0001689575-26-000030:0
1,285 shares@ US$84.21790.0053% mcap6.3% of flowClass A Common StockSEC:0001944119-26-000035:1
3,692 shares@ US$84.21780.015% mcap4.3% of flowClass A Common StockSEC:0001689575-26-000030:1
717 shares0Class A Common StockSEC:0001944119-26-000033:0
372 shares@ US$83.8390.0012% mcap2.2% of flowClass A Common StockSEC:0001944119-26-000033:1
3,576 sharesClass A Common StockSEC:0001534264-26-000002:0
3,576 sharesClass A Common StockSEC:0000943431-26-000002:0
3,576 sharesClass A Common StockSEC:0001200796-26-000002:0
3,576 sharesClass A Common StockSEC:0001307631-26-000002:0
3,576 sharesClass A Common StockSEC:0001585017-26-000002:0
3,576 sharesClass A Common StockSEC:0001753655-26-000002:0
25 of 710 declarations
About GeneDx Holdings Corp.
Between April 29, 2022 and May 20, 2022, 5 filers at GeneDx Holdings Corp. bought shares for EUR 77,303,987. Across the full history, 15 purchase filings are classed as clustered. The largest purchase is Eli Casdin's (Director): EUR 43,554,000 on April 29, 2022, then EUR 23,039,991 on January 31, 2023. On April 29, 2022, School of Medicine At Mount Sinai Icahn bought EUR 23,800,000. In all, 50 purchases worth EUR 167.5 million (median EUR 713,053), or 11% of open-market trades.
The 387 sales come to EUR 217.0 million, but with a median of only EUR 74,161. The largest are School of Medicine At Mount Sinai Icahn's (EUR 59,797,342 on October 31, 2024 and EUR 8,518,394 on November 18, 2024) and Casdin Capital, LLC's, filed as Director (EUR 52,055,174 on August 22, 2025). Kevin Feeley (CHIEF FINANCIAL OFFICER) has the most filings, 188, of which 123 sales.
Read moreShow less
708 filings from July 26, 2021 to September 18, 2026, peaking at 209 in 2025. A US healthcare and pharma company worth USD 1.98 billion. Last twelve months: 166 filings, 18 purchases, 107 sales. For the 50 purchases with a result, the 90-day median is 10.7%, with 52% of results positive (recorded past, not a forecast).
